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Molybdenum cofactor deficiency (MoCD) is an autosomal recessive inborn error of
metabolism characterized by neurodegeneration and death in early childhood. The rapid
and progressive neurodegeneration in MoCD presents a major clinical challenge and may
relate to the poor understanding of the molecular mechanisms involved. Recently, we
reported that treating patients with cyclic pyranopterin monophosphate (cPMP) is a
successful therapy for a subset of infants with MoCD and prevents irreversible brain
damage. Here, we studied S-sulfocysteine (SSC), a structural analog of glutamate that
accumulates in the plasma and urine of patients with MoCD, and demonstrated that it acts
as an N-methyl D-aspartate receptor (NMDA-R) agonist, leading to calcium influx and
downstream cell signaling events and neurotoxicity. SSC treatment activated the protease
calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin
subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic
synapses. Pharmacological blockade of NMDA-R, calcium influx, or calpain activity
abolished SSC and glutamate neurotoxicity in primary murine neurons. Finally, the NMDA-
R antagonist memantine was protective against the manifestation of symptoms in a
tungstate-induced MoCD mouse model. These findings demonstrate that SSC drives
excitotoxic neurodegeneration in MoCD and introduce NMDA-R antagonists as potential
therapeutics for this fatal disease.
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Introduction
Molybdenum cofactor deficiency (MoCD) is a rare metabolic 
disorder (1, 2) characterized by severe neurological abnormali-
ties including intractable neonatal seizures, feeding difficulties, 
developmental delay, ocular lens dislocation, and death in early 
childhood (3). More than 100 cases have been reported (2, 4, 5), 
the vast majority of which have been characterized by a severe 
neurological phenotype (6). However, because of a lack of diag-
nosis or misdiagnosis (7, 8), the global incidence of MoCD is 
probably underestimated, as the initial neurological symptoms 
of MoCD resemble a broad spectrum of metabolic and hypoxic 
encephalopathies (6, 9).
Patients with MoCD harbor mutations in the genes encod-
ing the enzymes molybdenum cofactor synthesis 1 (MOCS1), 
MOCS2, or gephyrin (GPHN) that are required for molybdenum 
cofactor (Moco) biogenesis (4, 10), a pathway that is highly con-
served throughout evolution. MoCD leads to the loss of activity 
of 4 molybdenum enzymes in humans (11) including sulfite oxi-
dase (SO). SO is a mitochondrial enzyme (12) that catalyzes the 
oxidation of toxic sulfite, generated from cysteine metabolism, 
to sulfate (10). The latter is required for multiple biochemical 
reactions including the sulfation of several substrates important 
for brain development (13, 14). MoCD has a clinical presentation 
similar to that of SO deficiency (SOD) disorder (15), implicating 
sulfite toxicity as the major pathomechanism in both diseases 
(10). Patients with MoCD have high levels of sulfite in their 
urine, which is accompanied by elevated urinary levels of tau-
rine and thiosulfate, while their plasma cystine level is depleted 
(10, 16). In addition, S-sulfocysteine (SSC), a secondary sulfur- 
containing metabolite, accumulates in the urine and plasma of 
MoCD patients and is used for MoCD diagnostics (10, 17).
Until recently, MoCD has been a fatal disease with a median 
life expectancy of 3 years (18). We introduced cyclic pyranopterin 
monophosphate (cPMP), the biosynthetic intermediate of Moco, 
as a new therapy for patients with MOCS1 mutations (19). Treat-
ment with cPMP normalized biomarkers and arrested neurode-
generation in a mouse model and in MoCD patients (19–21). In 
our recent prospective study (19), a remarkable clinical benefit 
was observed in patients treated soon after birth, who exhibited 
near-normal development. Treatment was less effective in 
patients who received delayed treatment (days to weeks after 
the manifestation of neurodegenerative symptoms) (19). While 
cPMP was effective in treating MoCD patients with MOCS1 
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prisingly, sulfite toxicity was also partially reversed by NMDA-R 
blockers (Figure 1, E and F). We hypothesized that sulfite reacted 
with cysteine and was converted to SSC in the culture medium. 
Under oxygenated conditions such as in serum and plasma, cyste-
ine is converted to its oxidized cystine form, while cellular reduc-
ing conditions favor the presence of the reduced cysteine form. 
We probed cystine and cysteine reaction with sulfite and found a 
cystine- and sulfite-dependent formation of SSC in a stoichiomet-
ric manner, while cysteine was not able to form SSC with sulfite 
(Supplemental Figure 2A), which supports the proposed extra-
cellular scavenging function of cysteine (10). Likewise, the addi-
tion of sulfite to neuronal culture medium resulted in a dose- 
dependent formation of SSC, which reached saturation as a result 
of a limited cystine concentration in the medium (Supplemental 
Figure 2B). When the toxicity of sulfite and SSC to cortical neu-
rons was assessed in cystine-containing (normal neuronal culture 
media) and cystine-free artificial cerebrospinal fluid (ACSF), we 
found that sulfite toxicity was reduced (58% cell viability) com-
pared with that of glutamate and SSC (34% and 33% cell viability, 
Figure 1G), and, in contrast to glutamate and SSC toxicity, MK801 
completely failed to rescue sulfite-mediated toxicity (Figure 1, E 
and F). Thus, sulfite itself is cytotoxic, as reported earlier (26), 
but develops more aggressive NMDA-R–dependent neurotoxicity 
upon reaction with cystine by forming SSC.
SSC evokes large tonic currents and calcium influx in cultured 
neurons. Given the structural and toxicological similarities of SSC 
and glutamate, we next investigated whether SSC could func-
tionally affect glutamatergic signaling. Voltage-clamp record-
ings of cultured primary hippocampal neurons (Figure 2, A and 
B) demonstrated that SSC, at its LD50 concentration (100 μM), 
caused rapid and reversible currents that were comparable to 
those evoked by 100 μM glutamate (Figure 2, A and B). How-
ever, as expected from our previous results, 100 μM sulfite (in 
cystine-free medium) had no effect on basal or postsynaptic cur-
rents (Figure 2B). We next tested SSC on somatic NMDA-Rs by 
examining the effect of the competitive NMDA-R antagonist APV 
(50 μM) and the noncompetitive NMDA-R antagonist MK801 (10 
μM) on SSC-evoked currents. Indeed, the SSC-evoked current 
amplitudes were decreased by the competitive antagonist APV 
(66.7% ± 7.8%; n = 7; P < 0.01) (Figure 2, C and D) and the non-
competitive antagonist MK801 (48.4% ± 6.7%; n = 3; P < 0.05) 
(Figure 2, C and D). The MK801 effect was not reversible after 
washout (Figure 2C), which is consistent with the very slow “off-
rate” of this open-channel blocker (27). Most notably, the residual 
current could be almost completely attenuated when NMDA-Rs 
and AMPA-type receptors were blocked simultaneously (remain-
ing current: 7.06% ± 5.00%, n = 5, P < 0.05) (Figure 2, E and F), 
indicating that SSC acts as an agonist of both types of ionotropic 
glutamate receptors in neurons.
Multiple studies have reported that excessive depolarization of 
the neuronal membrane potential due to stimulation of NMDA-R 
impairs calcium homeostasis, which can trigger multiple signaling 
cascades that lead to cell death (28–30). We further characterized 
NMDA-R activation by monitoring intracellular Ca2+ levels, which 
rise upon receptor stimulation. We used ratiometric Ca2+ imaging 
with fura-2 to compare cytosolic Ca2+ dynamics in cultured corti-
cal neurons that were induced by acute extracellular application 
mutations, alternative treatments are needed for patients with 
mutations in MOCS2 and GPHN (22), who have normal cPMP 
synthesis but impairment of subsequent steps of Moco synthesis.
In this study, we investigated the influence of MoCD metab-
olites on neurodegeneration and identified SSC as the main fac-
tor causing neuronal cell death. We provide in vitro and in vivo 
evidence that suppression of either SSC-mediated NMDA-R 
activation or subsequent downstream signaling events rescued 
SSC-triggered neurotoxicity. Furthermore, we demonstrate that 
SSC/NMDA-R/calcium signaling resulted in calpain-dependent 
cleavage of the postsynaptic scaffolding protein gephyrin, caus-
ing a destabilization of GABAergic synapses — which are the tar-
get of the anticonvulsive therapies currently used in MoCD (10, 
21). Therefore, our study provides a molecular understanding of 
the underlying pathomechanism that can be responsible for the 
intractable nature of seizures in patients with MoCD and provides 
a therapeutic strategy for symptomatic seizure control.
Results
Sulfite and SSC induce toxicity in cortical neurons. Sulfite, thiosul-
fate, taurine, and SSC levels are increased in the urine of patients 
with MoCD because of SO inactivity, while cysteine levels are 
reduced (10). We first explored whether the accumulated sulfur- 
containing metabolites (S-metabolites) induce neurotoxicity in 
primary murine cortical neurons. We compared the toxicities of 
the S-metabolites to that of glutamate, since SSC was suggested 
to cause neurotoxicity in MoCD (23), given its structural similar-
ity to glutamate (Figure 1A). After a 12-hour exposure, we used 2 
different assays to detect cell viability (MTT assay) and cell death 
(propidium iodide staining), which produced consistent results. 
Sulfite and SSC showed dose-dependent toxicity in cortical neu-
rons with LD50 values of 100 ± 3 μM and 74 ± 4 μM, respectively, 
which was similar to that of glutamate (82 ± 2 μM) (Figure 1, B and 
C). Taurine was not toxic, in agreement with its proposed protec-
tive role in the CNS (24, 25), while thiosulfate-mediated toxicity 
was low and only detected at high concentrations (LD50 = 621 ± 12 
μM). The toxicity of sulfite and SSC in cortical neurons was addi-
tionally confirmed using live/dead staining (Figure 1D and Sup-
plemental Figure 1; supplemental material available online with 
this article; https://doi.org/10.1172/JCI89885DS1). In contrast to 
neurons, in HEK293 cells, only sulfite was effective in inducing 
cell death (Figure 1D and Supplemental Figure 1), suggesting that 
SSC is not toxic per se but, like glutamate, acts specifically on glu-
tamatergic receptors.
SSC toxicity in MoCD involves NMDA-R activation. Early stud-
ies in rats showed that SSC, when administered intracerebrally, 
induces brain damage similar to that induced by glutamate (23). 
Given its structural similarity to glutamate, SSC was suggested to 
be neurotoxic (23), but this has yet to be explored as the underly-
ing cause of neurotoxicity in MoCD. We studied whether glutama-
tergic signaling by SSC mediates neurotoxicity in cortical neurons 
and compared this with other S-metabolites, in the absence and 
presence of the selective NMDA-R and α-amino-3-hydroxy-5- 
methyl-4-isoxazolepropionic acid receptor (AMPA-R) antagonists 
MK801 and NBQX, respectively. SSC-induced toxicity, like glu-
tamate toxicity, was abolished by the NMDA-R blocker MK801, 
but not by the AMPA-R blocker NBQX (Figure 1, E and F). Sur-
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spectrin, the major component of the cytoskeletal scaffolding 
network implicated in brain injuries (33–35), was used as a con-
trol. Indeed, SSC application (100 μM) to hippocampal neurons 
induced a time-dependent cleavage of both gephyrin and spec-
trin. Cleavage of both proteins was prevented in the presence of 
MK801 or a calpain-specific inhibitor (MDL-28170 or calpain 
inhibitor III) (Figure 4, A–C). In contrast, the excitatory postsyn-
aptic density protein 95 (PSD95) was less sensitive to SSC or glu-
tamate treatment, and no significant degradation of PSD95 could 
be detected (Figure 4, A and D). To assess the downstream impact 
of gephyrin cleavage on postsynaptic GABA type A receptors 
(GABAARs), which are clustered by gephyrin, we monitored 
gephyrin-positive GABAergic sites following incubation of neurons 
of glutamate or SSC (Figure 3, A–D). Glutamate and SSC induced 
indistinguishable cytosolic Ca2+ elevations (Figure 3, B and C), 
which were inhibited to a similar extent by MK801 (Figure 3D).
SSC decreases inhibitory synaptic input through calpain- 
dependent gephyrin degradation. In the course of excitotox-
icity, the Ca2+-dependent protease calpain cleaves a num-
ber of synaptic proteins at glutamatergic synapses, lead-
ing to synaptic loss and eventually neuronal cell death (31). 
Given that gephyrin, the major regulatory protein at inhib-
itory postsynapses (32), is also a calpain substrate, we test-
ed whether SSC-mediated Ca2+ influx leads to calpain- 
dependent cleavage of gephyrin (Figure 4) and loss of GABAergic 
synapses. The well-established calpain-dependent cleavage of 
Figure 1. Sulfite toxicity in neuronal 
tissue is mediated by SSC activation of 
the NMDA-R. (A) Chemical structure of 
glutamate and SSC. (B and C) Dose- 
dependent toxicity of taurine, thiosulfate, 
sulfite, SSC, and glutamate in cortical neu-
rons after a 12-hour incubation in culture 
medium, as assessed by MTT assay (n = 3) 
(B) or propidium iodide staining (n = 9) (C). 
Cultures were treated with either vehicle 
(control) or 10, 20, 50, 100, 200, and 500 
μM of each of the investigated metabo-
lites, and the LD50 values are highlighted 
for each metabolite using the MTT assay. 
(D) Representative images of live/dead 
staining under control conditions and in 
the presence of sulfite, SSC, or glutamate 
in primary neurons and HEK293 cells. 
Scale bars: 20 μm. The quantification of 
dead cells (red signal) was performed by 
measuring the fluorescence of ethidium 
homodimer-1 (n = 6 for each condition). 
(E and F) Cell viability of cortical neurons 
measured by (E) MTT assay for glutamate, 
SSC, sulfite, thiosulfate, and taurine (each 
200 μM) (n = 3) and (F) propidium iodide 
staining for glutamate, SSC, and sulfite 
at the same concentration (n = 12) in the 
presence of the NMDA-R blocker MK801 
(1 μM) and the AMPA-R blocker NBQX (20 
μM). (G) Cell viability of cortical neurons in 
ACSF media in the absence and presence 
of the NMDA-R blocker MK801 for gluta-
mate, sulfite, and SSC (n = 3). Data are 
presented as the mean ± SEM. **P < 0.01 
and ***P < 0.001, by 2-Way ANOVA with 
Dunnett’s (D–F) or Sidak’s (G) multiple 
comparisons test. FU, fluorescence units.
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neurons under the culture conditions used, which further sup-
ports the idea that SSC exerts its neurotoxicity from the extra-
cellular side (Supplemental Figure 3).
Pharmacological induction of MoCD in mice confirms SSC neu-
rotoxicity. To study the impact of SSC-mediated toxicity in vivo, 
we used a pharmacologically induced model of MoCD. Animals 
exposed to tungstate experience a dose-dependent replacement 
of molybdenum by tungsten during Moco synthesis, leading to 
the inactivation of all Moco-dependent enzymes (36, 37). Four-
week-old mice exposed to sodium tungstate at doses of up to 
1,000 ppm showed a dose-dependent decrease in liver SO activ-
ity (40% median decrease in 1,000 ppm versus control), while 
tungstate doses of 8,000 ppm led to a median decrease of 90% 
in SO activity when compared with controls (Figure 5A). This 
group of animals developed typical MoCD symptoms within 3 
weeks, including weight loss (Figure 5B), spontaneous twitch-
ing, hunched-back posture, and reduced mobility, all of which 
with SSC or glutamate (100 μM) (Figure 4E). Treatment with SSC 
or glutamate significantly decreased the gephyrin-positive cluster 
density (Figure 4F) and size (Figure 4, G and H), both of which 
were unchanged in the presence of MK801 or calpain inhibitor.
Since gephyrin is crucial for the function of inhibitory 
GABAergic synapses, these results indicate that cleavage of 
gephyrin upon SSC treatment could impair GABAergic inhibi-
tion and therefore augment NMDA-R–mediated excitotoxicity. 
To probe the contribution of each component of this pathway on 
SSC-mediated toxicity, we tested the NMDA-R blocker MK801, 
the Ca2+ scavenger BAPTA-AM, and the calpain inhibitor III 
(Figure 4, I and J) and found that they were individually equally 
effective in preventing SSC and glutamate toxicity (Figure 4, 
I and J), thus demonstrating an important contribution of the 
SSC-mediated NMDA-R opening/calcium influx/calpain acti-
vation cascade in the pathomechanism of MoCD. In accordance 
with this, we did not observe any cellular SSC uptake in cortical 
Figure 2. SSC, not sulfite, evokes 
somatic membrane currents 
and depolarizes the neuronal 
membrane potential. (A) Current 
traces of hippocampal neurons at 
–50 mV in the presence of 0.3 μM 
TTX and 100 μM sulfite, SSC, or 
glutamate. (B) Quantification of 
current amplitudes under basal 
conditions and in the presence 
of 100 μM sulfite, 100 μM SSC, or 
100 μM glutamate. (C) NMDA-R 
antagonists markedly decreased 
SSC-evoked current amplitudes 
in hippocampal neurons. (D) 
Quantification of the percentage 
of inhibition of tonic SSC–evoked 
currents by NMDA-R antag-
onists. Current amplitudes in 
the presence of 10 μM MK801 
or 50 μM APV were normalized 
to SSC-induced current peaks. 
(E) Application of both APV and 
DNQX almost completely blocked 
SSC-elicited currents. (F) Quan-
tification of the additive effect 
of NMDA-R and AMPA-R blocker 
on current amplitudes. Data are 
presented as the mean ± SEM. 
Numbers in parentheses in B, 
D, and F indicate the number of 
recorded neurons. *P < 0.05 and 
***P < 0.001, by 1-way ANOVA 
with Tukey’s multiple compari-
sons test.
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trast to Mocs1-KO mice (20), we observed neuronal cell death in 
tungsten-treated mice using Nissl staining, which revealed strong 
abnormalities in cerebral cortex and the CA1 region of the hippo-
campus of tungsten-treated animals (Figure 5G, arrows). Thus, 
our MoCD mice developed symptoms similar to those in patients, 
recapitulating the results obtained with cultured neurons and 
demonstrating the potential of SSC to act on glutamatergic path-
ways to induce neurodegeneration in MoCD.
Memantine improves the performance of MoCD mice. To eval-
uate the pharmacological potential for the use of NMDA-R 
antagonists in the treatment of MoCD, we tested memantine, 
an NMDA-R blocker used in the treatment of Alzheimer’s 
disease. In contrast to MK801, memantine is a low-affinity, 
uncompetitive antagonist able to inhibit prolonged Ca2+ influx, 
particularly from extrasynaptic receptors, without impairing 
receptor function at synapses. We first tested memantine in 
vitro and confirmed its potential to rescue SSC-mediated neu-
ronal cell death (Figure 6A) and gephyrin cleavage (Supplemen-
tal Figure 5), as was observed with MK801.
In healthy humans, SSC is normally not present in CSF at any 
detectable level (<1 μmol/l) (38), while in SOD, SSC levels of 19 
μmol/l were reported (38). In addition to our previous studies, we 
examined the potential of low SSC levels to induce cell death over 
a prolonged incubation period of 5 days in primary neurons. We 
became increasingly severe after 4 weeks of treatment (Supple-
mental Videos 1 and 2).
SSC levels in urine and brain extracts were elevated in 
tungsten-treated animals, with considerable variation in urine lev-
els (Figure 5, C and D), which correlated inversely with the residual 
activity of SO in each animal (Supplemental Figure 4, A and B). We 
analyzed a second cohort of mice and found similar SSC values in 
brain extracts, with a combined median of 72 nmol/mg protein for 
both cohorts (Fi gure 5D). We also found a moderate 2-fold increase 
in SSC levels in liver as compared with levels in controls, with a 
median of 1 nmol/mg protein, thus leading to a 70-fold increase 
in SSC levels in brain as compared with those in liver (Figure 5D). 
To our knowledge, this is the first report to demonstrate that SSC 
indeed accumulates dramatically in the brains of MoCD mice.
Consistent with our results in cultured neurons, gephyrin 
and spectrin degradation was observed in brain extracts from 
tungsten-treated animals (Figure 5E), while PSD95 levels were 
not altered (Figure 5F). In contrast, we observed no degrada-
tion of gephyrin or spectrin in liver, where both proteins are also 
expressed (Figure 5E), suggesting that SSC-mediated calpain 
cleavage of gephyrin and spectrin is exclusive to the brain and 
involves NMDA-R signaling. To further investigate brain injuries 
in tungsten-treated mice, we analyzed different brain sections 
from control and tungsten-treated animals (Figure 5G). In con-
Figure 3. SSC, like glutamate, induces calcium influx (32. (A) Fluorescence image (F380) of fura-2 AM–loaded cortical neurons. (B) Glutamate and SSC 
induced a similar Ca2+ influx. (B) Intracellular Ca2+ dynamics of a cortical neuron in response to a 10-second bath application of 100 μM glutamate (left 
trace) and 100 μM SSC (right trace). The images show the framed region of A at higher magnification and demonstrate the glutamate-induced increase 
in cytosolic Ca2+ concentration. The numbers indicate the time points of the traces when the images were taken. (C) Maximal amplitude and decay time 
constant of the glutamate- and SSC-induced rise in cytosolic Ca2+. The numbers in parentheses indicate the number of recorded neurons. (D) SSC-induced 
Ca2+ dynamics of a cortical neuron before, during, and after application of the NMDA-R blocker MK801. Data are presented as the mean ± SEM. Data were 
analyzed using a 2-tailed, unpaired Student’s t test.
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Figure 4. SSC-mediated calcium influx activates calpain and leads to gephyrin degradation. (A) Representative Western blots of spectrin, gephyrin, and PSD95 
in hippocampal neurons treated with glutamate (100 μM), SSC alone (100 μM), SSC plus calpain inhibitor (10 μM), or SSC plus MK801 (1 μM) at different time 
points. M, molecular weight marker. Quantification of band intensities of full-length and cleaved spectrin (B), gephyrin (C), and full-length PSD95 (D). At least 5 
Western blots per condition from 3 independent neuronal preparations were used. (E) Representative images of dendrites immunostained for gephyrin after a 
2-hour incubation with SSC, glutamate, or the indicated inhibitors. Scale bar: 5 μm (F) Gephyrin cluster density, (G) total fluorescence intensity of clusters, and (H) 
cumulative distribution of gephyrin cluster size in dendrites after treatment of neurons as in E (number of dendritic segments analyzed: control = 59; SSC = 67; 
glutamate = 71; SSC plus calpain inhibitor = 39; SSC plus MK801 = 54, from 2 independent cultures). (I and J) Time-dependent toxicity studies were conducted in 
cortical neurons for SSC (I) and glutamate (J) (each 200 μM) in the absence and presence of the NMDA-R blocker MK801 (1 μM), the calcium scavenger BAPTA-AM 
(10 μM), and calpain 1 inhibitor (10 μM). Data are presented as the mean ± SEM. **P < 0.01 and ***P < 0.001, by 2-way ANOVA with Dunnett’s (B–D and H–J) or 
Tukey’s (F and G) multiple comparisons test.
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found that SSC levels of 1 to 10 μM were able to induce neuronal 
cell death, which was reversed equally well by both memantine 
and MK801 treatment (Figure 6B). Furthermore, we observed a 
dose-dependent depolarization effect of SSC on membrane poten-
tial in the current-clamp recording condition (1 μM SSC, 2.22 ± 
0.76 mV, n = 3; 10 μM SSC, 29.02 ± 2.00 mV, n = 14; ***P < 0.001; 
100 μM SSC, 43.62 ± 0.92 mV, n = 16; ***P < 0.001) (Figure 6C). 
These results demonstrate that even low concentrations of SSC can 
induce strong depolarizations of the neuronal membrane potential 
and, hence, that SSC is a strong excitatory neurotransmitter.
Finally, we tested the impact of memantine on a separate 
cohort of tungstate-treated mice, both to validate the molecular 
pathway we propose and to demonstrate the potential of meman-
tine as a new therapeutic for MoCD. Because of the severity of 
the disease observed in the first cohort of mice (molybdenum- 
deficient diet and tungsten supplementation), which resulted 
in death after 4 weeks of treatment, the mice were fed a nor-
mal diet (normal molybdenum content), and their drinking 
water was supplemented with the same effective tungsten dose 
(8,000 ppm) used previously, which allowed the experiment to 
be conducted for more than 5 weeks. Mice received i.p. injec-
tions of memantine twice a week, and the mice were assessed 
weekly for body weight and motoric performance using the 
rotarod instrument.
To exclude tungsten enrichment in neuronal tissue, which 
may indicate direct tungsten neurotoxicity in our pharmacologi-
cal mouse model, we measured tungsten levels in the livers, kid-
neys, and brains of the treated mice using inductively coupled 
plasma mass spectrometry (ICP-MS) at the end of the study. We 
found that tungsten levels were elevated in the liver and kidneys 
of the mice (organs with the highest capacity for Moco synthesis 
and sulfite oxidation [ref. 22]), however, none of the mice had 
elevated tungsten levels in the brain. We also found that tungsten 
levels were not altered by memantine treatment. These findings 
indicate that the observed effects of tungsten intoxication are due 
to the loss of SO activity in the periphery and not to direct neu-
rotoxicity of tungsten (Supplemental Figure 6A). Additionally, in 
vitro data showed that neuronal cell lines are less susceptible to 
tungsten toxicity than are HEK293 cells (Supplemental Figure 
6B). Consistent with our previous results (Figure 5B), tungsten 
treatment induced progressive weight loss in mice (Figure 6D) 
and a significant decrease in rotarod motoric performance 
(Figure 6E) after 4 and 5 weeks of treatment. More important, 
memantine treatment completely rescued tungsten-induced 
weight loss and rotarod impairment after 4 and 5 weeks of treat-
ment (Figure 6, D and E). In accordance with our in vitro data, 
memantine was also able to decrease gephyrin degradation in 
both control and tungsten-treated animals, while no degradation 
was observed for PSD95 (Figure 6F), thus demonstrating the 
therapeutic potential of NMDA-R antagonists in MoCD.
In summary, we demonstrated the following sequence of 
events accounting for neuronal cell death in MoCD: (a) SOD 
induces a systemic increase in sulfite, (b) sulfite accumulation 
results in SSC formation within the periphery as well as the brain 
following the reaction of excess sulfite with cystine, and (c) SSC 
induces excitotoxicity via NMDA-R–dependent calcium signaling 
and calpain activation (Figure 6G).
Discussion
Although MoCD results in the deficiency of 4 enzymes in humans, 
SOD is generally accepted as the major cause of brain damage in 
MoCD (2). Little is known about the metabolites involved in neuro-
nal cell death in MoCD; the purpose of this study was to determine 
the underlying pathomechanism of the disease, in particular, the 
potential involvement of the S-metabolites. We identified and con-
firmed sulfite and SSC as the main mediators of neuronal toxicity. 
Sulfite toxicity has been investigated in the past and was proposed 
as the major trigger of neuronal cell death in MoCD (4, 20). Sulfite 
increases oxidative stress and reduces ATP synthesis in mitochon-
dria respiring on glutamate (26). Sulfite is a strong reductant and 
reacts with disulfide bonds in proteins (26) and cystine, which we 
demonstrated in vitro in this study. High levels of excreted SSC and 
sulfite, together with cystine depletion, are characteristic of human 
patients, supporting the hypothesis that an excess of sulfite crosses 
the blood-brain barrier to cause neurodegeneration.
In addition to sulfite, our data identified SSC as the major 
trigger of neuronal cell death in MoCD. SSC-mediated activa-
tion of NMDA-R and AMPA-R led to dose-dependent depolar-
ization of the neuronal membrane potential, which increased 
neuronal excitability and intracellular calcium levels and 
triggered the activation of downstream cell death pathways. 
In particular, we found that the calcium-dependent protease 
calpain was activated upon exposure of neurons to SSC (and 
glutamate), which upregulated the degradation of neuronal 
proteins and cell death. SSC-triggered neurotoxicity could be 
rescued with an NMDA-R antagonist, calcium scavenger, and 
calpain inhibitor. The action of SSC on neuronal cells was phar-
macologically indistinguishable from that of glutamate. How-
ever, the selective enrichment of SSC found in the brains of 
tungsten-treated mice compared with that found in livers may 
indicate the lack of an efficient SSC clearance from the brain, 
which would result in a prolonged overstimulation of ionotropic 
glutamate receptors and enhanced excitotoxicity. It should be 
noted that the SSC levels determined here were measured in 
total brain extracts, and future studies are required to deter-
mine the reference values for extracellular/CSF levels of SSC, 
which would be more informative and predictive of neuronal 
damage. Because SSC toxicity was restricted to neuronal cells 
in contrast to sulfite, and given the severe neurological symp-
toms characteristic of MoCD, we argue that SSC is the principal 
mediator of neurotoxicity in MoCD.
Gephyrin plays a crucial role in the clustering and plasticity 
of inhibitory synapses (32, 39), and either genomic deletions or 
miss-splicing within the GPHN gene has been linked to neurolog-
ical disorders such as epilepsy (40, 41), schizophrenia, and hyper-
ekplexia (42, 43). Furthermore, gephyrin is also crucial for Moco 
synthesis, as it catalyzes the 2-step metal insertion reaction (44). 
Consistent with this, Gphn-KO mice exhibit a neurological phe-
notype more severe than that of MoCD; indeed, homozygous-KO 
mice die within the first day of life (45). Our finding of an SSC- 
mediated reduction in GABAergic transmission, accompanied 
by pronounced depolarization of the neuronal membrane poten-
tial, suggests that the increased neuronal excitability in neuronal 
circuits of MoCD patients contributes to the severity of their sei-
zures, followed by rapidly progressing loss of brain tissue (Figure 
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SSC/NMDA-R/calcium signaling resulted in calpain-dependent 
cleavage of the postsynaptic scaffolding protein gephyrin, caus-
ing a destabilization of GABAergic synapses. GABAergic neuro-
transmission is a common target for anticonvulsive therapies, 
and patients with MoCD are often treated with phenobarbital 
and midazolam (10, 21). Moreover, our study reveals a therapeu-
tic strategy for the treatment of MoCD by targeting NMDA-Rs, 
e.g., with memantine, which has been shown to be safe and well 
tolerated (48). Given our recent clinical findings on MoCD type 
A patients who were treated with cPMP (19), early diagnosis and 
a better understanding of the underlying disease mechanism are 
crucial for treatment success. Therefore, any treatment aimed 
at delaying neuronal cell death triggered by SSC-mediated 
NMDA-R activation will increase the time window of treatment 
for patients who can benefit from cPMP treatment. Our results 
strongly suggest that targeting the NMDA-R by antagonists 
would be beneficial in preventing SSC-induced brain damage. 
This approach is supported by a previous report of a patient with 
MoCD who had a promising outcome (49). Furthermore, the cur-
rent classical anticonvulsive treatment for symptomatic MoCD 
patients is characterized by a progressive lack of treatment 
response, which, in light of the findings in this study, could be 
explained by the reduction in GABAergic synapses. In summa-
ry, we believe this study translates a mechanistic understanding 
into a new concept for disease management and potential new 
therapies for a devastating excitotoxic disease.
Methods
 Cell culture and toxicity studies. Human embryonic kidney cells 
(HEK293) were cultivated in DMEM supplemented with 10% FCS 
and 2 mM L-glutamine at 37°C and 5% CO2. Primary neuron cul-
tures were prepared from hippocampi or cortex of C57BL/6 mice and 
cultured in neurobasal medium supplemented with B-27, N-2, and 
L-glutamine. All reagents were supplied by Life Technologies (Ther-
mo Fisher Scientific). Neurons were cultivated at different densities 
depending on which culture plate was used (30,000/well for 96-well 
plates, 75,000/well for 24-well plates, and 900,000/well for 6-well 
plates). For confocal laser-scanning microscopy, neurons and HEK293 
cells were cultivated on poly-L-lysine–coated and collagenized cover-
slips, respectively. Unless otherwise stated, all neuronal studies were 
conducted after 9 to 10 days in vitro (DIV).
Toxicity studies using the MTT assay were conducted in 96-well 
plates for 12 hours in the presence of 200 μM of each investigated 
metabolite, unless otherwise stated. For selective neuronal toxicity stud-
ies, 2 different receptor blockers were used: MK801 for NMDA-Rs and 
NBQX for AMPA-Rs, at a final concentration of 1 and 20 μM, respect-
ively. All amino acids and S-metabolites (sulfite, thiosulfate, taurine and 
S-sulfocysteine) were purchased from MilliporeSigma, and MDL-28170 
(Santa Cruz Biotechnology) was used as a cell-permeable selective 
inhibitor of calpain 1. For toxicity experiments in cystine-free medium, 
neuronal medium was exchanged for an ACSF solution (124 mM NaCl, 
2.5 mM KCl, 2.5 mM CaCl2, 1.25 mM KH2PO4, 2 mM MgSO4, 26 mM 
NaHCO3, 1.3 mM MgCl2, 10 mM glucose, 4 mM sucrose), and neurons 
were incubated for 1 hour prior to the start of the experiment.
Cell viability assay. Cell viability studies were conducted using 
either the MTT assay (Promega) or propidium iodide staining 
(MilliporeSigma). Cortical neurons (DIV 10) were cultivated in a 
6C). The sequence of events identified in this study is supported 
by previous findings of maladaptive changes in gephyrin function 
as a pathogenic factor in epilepsy (40, 41, 46, 47).
We previously characterized the genetic mouse model of 
human MoCD (20). Mocs1-KO mice display symptoms resem-
bling human MoCD, and these mice were successfully used for 
the development of the first treatment of human MoCD (20). 
However, Mocs1-deficient mice die within the first 11 days after 
birth, without visible brain injuries such as atrophy, cysts, or loss 
of cortical tissue (20). The lack of overt neuropathological chang-
es, probably due to the mouse’s short lifespan, limits the use of this 
genetic mouse model to investigate the process of neurodegener-
ation in MoCD. We therefore used a tungstate treatment model 
of MoCD, which has been successfully used in rats to induce SOD 
(37). Pharmacological induction of MoCD in older mice allows 
for prolonged disease development and a more detailed obser-
vation of brain pathologies. Tungsten-treated mice developed 
symptoms similar to those observed in human patients, including 
weight loss, motoric weakness, and neuronal cell death. In addi-
tion, we showed that brain extracts from tungsten-treated mice 
had SSC accumulation and gephyrin and spectrin cleavage and 
that PSD95 levels were unaffected. We showed a specific accu-
mulation of SSC in brain tissue, which may suggest prolonged 
neuronal excitotoxicity and explain the rapid and progressive 
neuronal cell death observed in human patients. Although, CSF 
levels of SSC would be more informative of the severity of the 
pathological condition, it should be noted that SSC is close to 
detection limits under normal conditions and that SSC only accu-
mulates under disease conditions such as MoCD and SOD. This is 
consistent with the accumulation of SSC in biological fluids such 
as urine and plasma, which is used as a disease-predicting and 
treatment-monitoring biomarker (10, 17, 38).
In summary, our study provides both in vitro and in vivo 
evidence that SSC is a major neurotoxic agent in MoCD. SSC is 
generated by the reaction of sulfite with cystine and was found 
to specifically accumulate in the brain. Suppression of either 
SSC-mediated NMDA-R activation or downstream signaling 
events is sufficient to rescue neuronal survival. We found that 
Figure 5. Induction of MoCD in mice prompts SSC formation and neuronal 
cell death. (A) Liver SO activity in mice after 4 weeks of treatment (n = 7/
group). (B) Assessment of body weights (n = 32 mice/treatment group) of 
male and female mice. (C) SSC accumulation in urine (n = 7 control mice,  
n = 9 tungsten-treated mice). (D) Normalized SSC levels in extracts of brain 
(black circles and white squares represent 2 individual mice cohorts; n = 12 
control, n = 13 SSC) and liver (n = 7 control, n = 6 SSC). (E) Calculated SSC 
concentration in brain extracts from D (n = 12 control, n = 13 SSC). (E and 
F) Immunoblots showing the expression of gephyrin and spectrin in brain 
and liver extracts (E) and the expression of PSD95 in brain extracts (F) from 
control and tungsten-treated mice (n = 4/group). (G) Nissl-stained images 
of brain sections from control and tungsten-treated mice, with represen-
tative sections of cortical and hippocampal regions and quantification of 
neuronal density and size in cortex (layers 1 and 2) and hippocampal CA1 
regions (n= 32 cortex, n = 18 CA1, derived from 3 mice/group). Scale bar:  
200 μm. Data are presented as the mean ± the SEM. Red lines indicate 
the median value. **P < 0.01 and ***P < 0.001, by 2-way ANOVA with 
Dunnett’s multiple comparisons test (A), 2-tailed, unpaired Student’s t 
test (B and C), 1-way ANOVA with Tukey’s multiple comparisons test (D), or 
2-tailed, paired Student’s t test (G).
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Figure 6. NMDA-R antagonist is beneficial for the treatment of MoCD in mice. (A) Cell viability of cortical neurons with SSC (200 μM) was assessed with 
propidium iodide staining in the absence and presence of the NMDA-R blocker MK801 (1 μM) or memantine (10 μM) after a 12-hour incubation in culture 
medium (n = 15). (B) The toxic effect of low levels of SSC (1 and 10 μM) was assessed using propidium iodide staining in cortical neurons after a 5-day 
incubation in the absence and presence of MK801 (1 μM) or memantine (10 μM) (n = 15). (C) Recordings in the current-clamp mode revealed a dose- 
dependent effect of SSC on depolarization of the neuronal membrane potential. Graph represents the quantification of SSC-induced depolarization of 
the membrane potential. Numbers in parentheses represent the number of recorded neurons. (D and E) Efficacy of memantine treatment in the tungsten 
treatment study was evaluated by body weight (D) and motoric performance using rotarod testing (E) in the different mouse groups (n = 10 mice/group). 
(F) Immunoblot shows that memantine treatment decreased gephyrin degradation bands in control and tungsten-treated animals, while no degradation 
was observed with PSD95 (n = 6 mice/group). (G) Proposed sequence of events causing neurodegeneration in MoCD and SOD. Data are presented as the 
mean ± SEM. **P < 0.01 and ***P < 0.001, by 2-way ANOVA with Dunnett’s multiple comparisons test (A, B, D, and E), 1-way ANOVA with Tukey’s multiple 
comparisons test (C), or 2-tailed, unpaired Student’s t test (F).
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(Santa Cruz Biotechnology; sc-46696; 1:150); anti–β-tubulin (Mil-
liporeSigma; T7816; 1:10,000); and anti–β-actin (MilliporeSigma; 
AC-47; 1:10,000). Secondary antibodies were from Santa Cruz Bio-
technology and were used at 1:5,000 dilution.
Immunostaining and image processing. Immunostaining was per-
formed for the visualization and quantification of gephyrin clusters. 
Neurons (DIV 12–13) were fixed with 4% paraformaldehyde and 
blocked with blocking solution (2% BSA, 10% goat serum, 0.2% Tri-
ton in PBS) for 1 hour. Primary antibodies (anti-gephyrin, clone 3B11) 
were applied for 1 hour in blocking solution. After 3 washing steps in 
PBS, neurons were incubated with secondary antibodies in 2% BSA 
and 0.2% Triton for 1 hour and washed extensively with PBS, and 
the slides were mounted on coverslips with Fluoro gel II containing 
DAPI (Science Service).
Images were taken with a Nikon AZ-C2+ confocal laser-scanning 
microscope as a Z-stack of 3 optical sections with a 0.5-mm step size. 
Maximum intensity projections were created and analyzed using 
Nikon NIS Elements 3.2 software. Regions of interest (ROIs) (20 × 5 
mm) were placed on dendrites, and clusters were quantified using the 
analyze particles option in NIS Elements. Only clusters between 0.09 
μm² and 2 μm² in size were considered. For statistical analysis, values 
of individual ROIs were averaged, and mean values were compared 
for significance using a 2-tailed Student’s t test. Cumulative distri-
bution of gephyrin cluster size and statistics were calculated using 
GraphPad Prism 6 (GraphPad Software).
Electrophysiologic recordings. Whole-cell patch-clamp recordings 
were performed on cultured hippocampal neurons at 15 to 23 DIV. An 
EPC-7 amplifier and PATCHMASTER software (HEKA) were used for 
the recordings. Patch pipettes, made from borosilicate glass (Science 
Products), had resistances of 3 to 6 MΩ when filled with the intracel-
lular solution containing 130 mM CsCl, 5 mM NaCl, 0.5 mM CaCl2, 
1 mM MgCl2, 5 mM EGTA, and 30 mM HEPES (pH 7.2) was adjusted 
with CsOH. The standard extracellular solution (pH 7.4) contained 
140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES-
NaOH, and 10 mM glucose. Cells were recorded in voltage-clamp and 
current-clamp modes. For recording in voltage-clamp mode, cells 
were clamped at a potential of –50 mV. Series resistances (Rs) were 
monitored by applying –5 mV voltage pulses (50 ms) every 5 seconds 
and ranged between 5 MΩ and 30 MΩ. Experiments with a change of 
more than 25% in Rs throughout the recording were not included in 
the analyses. Cells were also recorded in current-clamp mode. In this 
case, the resting membrane potential of all recorded cells was deter-
mined directly after break in and ranged between –33 and –55 mV 
(n = 33). Series resistances (Rs), monitored in voltage clamp by –5 mV 
voltage pulses (50 ms), were between 10 MΩ and 40 MΩ. For investi-
gation of changes in membrane potential induced by SSC application, 
the holding current was adjusted so that the membrane potential of 
the neuron was at -50 mV. Cells needing >200 pA current injection 
were not included. Depolarization of membrane potential induced by 
local SSC application was measured in the presence of tetrodotoxin 
(TTX) (0.3 μM; MilliporeSigma). Data were acquired with a sampling 
rate of 10 kHz after filtering at 2.8 kHz. All experiments were per-
formed at room temperature (20°C–25°C). Quantitative analysis of 
parameters was performed using in-house software written in IGOR 
6.32A (WaveMetrics) and using Patcher’s Power Tools.
Calcium imaging. Cytosolic Ca2+ dynamics were determined by 
ratiometric Ca2+ imaging with fura-2. The imaging set-up consisted 
96-well tissue culture plate at a density of 30,000 cells/well, and tox-
icity experiments were started by the addition of different metabolites 
and blockers to each well, followed by an incubation step of 12 hours 
(unless otherwise stated) at 37 °C in a humidified, 5% CO2 atmosphere. 
Finally, cell viability was evaluated according to the supplier’s protocol 
by measuring absorption at 570 nm (reference 650 nm) for the MTT 
assay and fluorescence at 620 nm (excitation 530 nm) for propidium 
iodide staining using a well plate reader (Tecan). The same procedure 
was used for measuring tungsten toxicity in different cells.
Live/dead staining: For discrimination between neuronal and 
non-neuronal toxicities, HEK293 and cortical neurons were culti-
vated separately on coverslips in a 24-well plate, and cell viability 
in the presence of the investigated metabolites (same protocol as 
the MTT assay) was evaluated using a live/dead staining kit, which 
allows the simultaneous fluorescence-based determination of live 
and dead cells (Life Technologies, Thermo Fisher Scientific). Quan-
tification was carried out in a well plate reader by measuring the 
fluorescence in 24-well plates at 530 nm (live cells, green signal 
measuring calcein fluorescence) and 645 nm (dead cells, red signal 
measuring ethidium homodimer-1 fluorescence) according to the 
supplier’s protocol, and representative images were taken from the 
same plates using confocal laser-scanning microscopy.
Amino acid quantification and uptake. Quantification of glutamate and 
SSC was performed using precolumn derivatization and reversed-phase 
chromatography as previously described (17). For SSC quantification in 
protein extracts from brain, liver, or cultured neurons, metabolites were 
normalized to the protein amount, and for SSC quantification in urine, 
the determined concentrations were normalized to creatinine, which was 
determined using the Jaffe method as previously described (17).
Transport of the amino acids glutamate and SSC were examined 
in cortical neurons (DIV 10) cultured in 6-well plates at a density of 
900,000 cells/well according to the following protocol: Neuronal media 
were removed and replaced by ACSF solution, and cells were allowed to 
incubate for 1 hour at 37 °C. The investigated metabolites were then added 
in a final concentration (if not otherwise stated) of 100 μM and incubated 
with the cells for 1 hour at 37°C. The ACSF medium was then removed, 
and cells were washed twice with ice-cold balanced salt solution (BSS) 
(137 mM NaCl, 5.4 mM KCl, 10 mM Tris/HCl, pH 7.6) and resuspend-
ed in 300 μl 0.1 M NaOH. After a centrifugation step for removal of cell 
debris (15,000 g, 10 min), the supernatant was divided in aliquots for 
determination of protein concentration and amino acid quantification 
using HPLC. The amount of transported metabolites was normalized to 
the total extracted proteins and quantified in nmol/mg protein.
Western blot analysis. Western blotting was performed on protein 
crude extracts prepared either from cultivated and treated neurons 
or from mouse crude extracts of liver and brain derived from con-
trol and tungsten-treated animals. Protein lysates were separated 
by SDS-PAGE and immunoblotted using standard protocols. Mem-
branes were probed with HRP-conjugated secondary antibodies, 
and signal was detected using an ECL system equipped with a cooled 
Chemiluminescence DeVision HQ2 camera system and Gel-Pro 
Analyzer software (Decon Science Tec). For band intensity quan-
tification, the images were converted to 8-bit, the background was 
subtracted, and the bands were selected manually with the freehand 
function and automatically analyzed using ImageJ, version 1.48 
(NIH). The primary antibodies used were: anti-gephyrin (Synaptic 
Systems; clone 3B11; 1:50 cell culture supernatant); anti-spectrin 
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were placed on the rotarod and allowed to acclimatize at a constant base-
line speed of 3.5 rpm before allowing the rod to accelerate to 40 rpm for 
5 minutes, with an acceleration interval of 6 seconds, and the latency to 
fall within this time period was recorded. Trials were conducted once per 
week, and data from all the trials were used to evaluate the motor coordi-
nation and balance of each mouse during the experiment.
Brain sectioning. For tissue preparation, control and tungsten- 
treated mice were anesthetized by i.p. injection of xylazine/ketavet 
and perfused by intracardiac perfusion with 0.1 M PBS, followed by 
4% paraformaldehyde in 0.1 M PBS. The mouse brains were then 
prepared and fixed in 4% paraformaldehyde in 0.1 M PBS at 4°C 
overnight. Coronal sections (30-μm-thick) were cut with a vibratome 
(Leica Biosystems), collected in ice-cold 0.1 M PBS, and stored in PBS 
with 0.1% sodium azide until further processing. 
Nissl staining. Stored brain sections were washed with PBS, 
mounted on gelatine-coated slides, and air-dried for 60 minutes. The 
sections were then incubated for 5 minutes in 0.1% prewarmed (50°C) 
cresyl violet solution (MilliporeSigma) and rinsed in water twice. 
Cresyl violet–stained sections were destained and dehydrated with 
ascending series of ethanol, cleared with xylene for 5 minutes, and 
coverslipped using Permount Mounting Medium (VWR). Slides were 
then scanned using the Leica SCN400 Slide Scanner.
SO activity measurements. SO activity was measured in crude liver 
extracts from control and tungsten-treated mice using the sulfite:cyto-
chrome c activity assay. Briefly, 50 μg crude protein extract was incu-
bated in a 200-μl mixture (final volume) containing 50 mM Tris/ace-
tate, pH 8, 0.2 mM deoxycholic acid, 0.1 mM potassium cyanide, and 
0.5 mM sodium sulfite, and the reaction was started by adding 12 μl 
cytochrome c (10 mg/ml). SO activity was determined by monitoring 
the absorption change of cytochrome c at 550 nm (ε550 = 19630/M/cm). 
All activity was measured at room temperature (25°C) using a 96-well 
plate reader (BioTeK).
Statistics. All numerical data are presented as the mean ± SEM. 
All experiments were performed at least 3 times, and statistical anal-
yses were performed using GraphPad Prism 6 (GraphPad Software) 
with 1- or 2-way ANOVA with multiple comparisons for analysis of 3 
or more groups, whereas a 2-tailed Student’s t test was only used for 
comparisons of fewer than 3 groups. For statistical analyses of the 
different mice groups, the median value was used, and the difference 
between 2 groups was considered statistically significant if the P val-
ue was less than 0.05.
Study approval. All experiments involving animals complied with local 
and international regulations and ethics guidelines and were approved 
by the local research ethics committees (Germany, Landesumweltamt 
Nordrhein-Westfalen, reference 87-51.04.2011.A014, and Melbourne, 
Australia, Florey Animal Ethics Committee, reference 15-041-FINMH).
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of a Zeiss AxioCam/MRm CCD camera with a 1388 × 1040 chip 
and a Polychromator V (Till Photonics) that was coupled via an 
optical fiber to a Zeiss AxioExaminer upright microscope equipped 
with a ×40 W Plan Apochromat objective (numerical aperture 1). 
The camera and Polychromator were controlled by Axiovision 
software including the Physiology Module (release 4.8.2 SP3; 
Zeiss). During data collection, the fura-2–loaded neurons were 
excited with 340 nm or 380 nm. Image pairs were recorded with 
5.6 Hz and exposure times of 50 ms for each wavelength. Emitted 
fluorescence was detected through a 465- to 555-nm band-pass fil-
ter (BP510/90). Images were recorded in analog-to-digital units 
(ADUs) and stored and analyzed as 16-bit grayscale images. Ca2+ 
dynamics were determined from the ADU mean of the cell bodies. 
ROIs were defined by the soma border.
For imaging experiments, coverslips with fura-2–loaded neurons 
were transferred to a 1-ml recording chamber and constantly superfused 
with physiological saline at a flow rate of approximately 5 ml/min. The 
saline contained 125 mM NaCl, 5.5 mM KCl, 10 mM CaCl2, 0.8 mM 
MgCl2, 10 mM HEPES, 24 mM glucose, and 12.5 mM sucrose, adjusted to 
pH 7.3 with NaOH. Sulfinpyrazone (0.25 mM) (MilliporeSigma; S9509) 
was added to reduce fura-2 sequestration. Ca2+ influx was induced by 
a 10-second bath application of 100 μM glutamate or SSC. To test the 
effect of the NMDA antagonist MK801 on these responses, MK801 (10 
μM) was added to the imaging solution before and during the applica-
tion of glutamate and SSC. Fura-2 was AM-loaded into cultured mouse 
cortical neurons by incubating cells with 10 μM fura-2 AM (Molecular 
Probes; F1221) dissolved in imaging solution (37°C for 30 min). Fura-2 
was prepared in a stock solution (50 μg in 5 μl DMSO). The final DMSO 
concentration in the loading solution was 0.1 % (v/v). Changes in cal-
cium concentration were given as the normalized (to the resting state) 
changes in the fluorescence ratio (R = F340/F380). Analysis was performed 
offline using Axiovision and GraphPad Prism 6 (GraphPad Software).
Tungsten treatment study. Four-week-old WT C57BL/6 mice were 
divided into two groups of control and tungsten-treated animals. The 
control group (n = 32) was fed a normal diet and normal drinking water, 
and the tungsten-treated group (n = 32) received a molybdenum-free 
diet, and their drinking water was supplemented with 8,000 ppm sodi-
um tungstate, except for the initial experiments, in which different 
sodium tungstate concentrations were tested (100, 800, and 1,000 
ppm). Male and female mice were equally distributed between the 2 
groups, and there was no discrimination between the sexes, except 
when comparing body weight loss between the groups. The experiment 
was terminated at the end of week 4, and all mice were sacrificed and 
divided into small groups for different analyses.
Memantine and SSC treatment studies. For the memantine study,4 
experimental groups of 10 mice were divided into 2 control groups and 
2 tungsten-treated groups, with each group receiving i.p. injections of 
either saline or memantine (5 mg/kg body weight) twice a week. For 
the SSC study, 2 experimental groups of 10 mice were divided into 1 
control and 1 SSC group receiving i.p. injections of either saline or SSC 
(5 mg/kg body weight) twice a week. Weekly measurement of body 
weight and rotarod performance was done for each mouse, and after 
6 weeks, all the mice were euthanized and perfused, and the organs 
(liver, kidney and brain) were collected for biochemical analysis.
Rotarod testing. The rotarod instrument (Sandown Scientific; Ugo 
Basile, model 7650) was used to measure the motoric performance of 
mice. Mice were first familiarized with the task prior to testing. Mice 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 3 7 7jci.org   Volume 127   Number 12   December 2017
Institute of Neuroscience and Mental Health acknowledges the 
substantial support received from the Victorian Government and 
in particular the Operational Infrastructure Support Grant.
Address correspondence to: Guenter Schwarz, Institute of Bio-
chemistry, University of Cologne, 50674 Cologne, Germany. 
Phone: 49.221.470.6440; Email: gschwarz@uni-koeln.de. Or 
to: Abdel Ali Belaidi, The Florey Institute of Neuroscience and 
Mental Health, The University of Melbourne, 30 Royal Parade, 
Parkville, Victoria 3052, Australia. Phone: 61.3.8344.8469; Email: 
abdel.belaidi@florey.edu.au.
Cologne, Institute of Biochemistry, Cologne, Germany); Helmut 
Wratil (University of Cologne, Institute of Zoology, Cologne, Ger-
many); and Steve Moon, Ambili Appukuttan, and Irene Volitakis 
(The University of Melbourne, The Florey Institute of Neurosci-
ence and Mental Health, Melbourne, Australia). This work was 
supported by the Center for Molecular Medicine Cologne (CMMC 
(grant D05, to GS); the Bundesministerium für Bildung und For-
schung BMBF (ERA-Net Neuron II, project CIPRESS, to JCM); the 
Deutsche Forschungsgemeinschaft (DFG)  (Priority Programme 
SPP 1784 ME2075/7-1, to JCM); and the National Health and 
Medical Research Council of Australia (AF79, to AIB). The Florey 
 1. Johnson JL, Waud WR, Rajagopalan KV, 
Duran M, Beemer FA, Wadman SK. Inborn 
errors of molybdenum metabolism: combined 
deficiencies of sulfite oxidase and xanthine 
dehydrogenase in a patient lacking the molyb-
denum cofactor. Proc Natl Acad Sci U S A. 
1980;77(6):3715–3719.
 2. Johnson JL, Duran M. Molybdenum cofactor defi-
ciency and isolated sulfite oxidase deficiency. 
In: Scriver C, Beaudet A, Sly W, Valle D, eds. The 
metabolic and molecular bases of inherited disease. 
New York, NY: McGraw-Hill; 2001:3163–3177.
 3. Duran M, et al. Combined deficiency of xanthine 
oxidase and sulphite oxidase: a defect of molyb-
denum metabolism or transport? J Inherit Metab 
Dis. 1978;1(4):175–178.
 4. Reiss J, Hahnewald R. Molybdenum cofactor 
deficiency: Mutations in GPHN, MOCS1, and 
MOCS2. Human mutation. 2011;32(1):10–18.
 5. Bayram E, et al. Molybdenum cofactor deficien-
cy: Review of 12 cases (MoCD and review). Euro-
pean journal of paediatric neurology: EJPN: official 
journal of the European Paediatric Neurology Soci-
ety. 2013;17(1):1–6.
 6. Vijayakumar K, et al. Clinical neuroimaging fea-
tures and outcome in molybdenum cofactor defi-
ciency. Pediatric neurology. 2011;45(4):246–252.
 7. Kikuchi K, Hamano S, Mochizuki H, Ichida K, 
Ida H. Molybdenum cofactor deficiency mimics 
cerebral palsy: differentiating factors for diagno-
sis. Pediatric neurology. 2012;47(2):147–149.
 8. Waring WS, Maxwell S. Diagnosis of 
molybdenum cofactor deficiency. Lancet. 
1999;353(9153):675–676.
 9. Topcu M, Coskun T, Haliloglu G, Saatci I. Molyb-
denum cofactor deficiency: Report of three cases 
presenting as hypoxic-ischemic encephalopathy. 
J Child Neurol. 2001;16(4):264–270.
 10. Schwarz G, Belaidi AA. Molybdenum in 
human health and disease. Met Ions Life Sci. 
2013;13:415–450.
 11. Schwarz G, Mendel RR, Ribbe MW. Molybde-
num cofactors, enzymes and pathways. Nature. 
2009;460(7257):839–847.
 12. Klein JM, Busch JD, Potting C, Baker MJ, Langer T, 
Schwarz G. The mitochondrial amidoxime- 
reducing component (mARC1) is a novel signal- 
anchored protein of the outer mitochondrial mem-
brane. J Biol Chem. 2012;287(51):42795–42803.
 13. Ryaskin OT, ed. Trends in autism research. New 
York, NY: Nova Biomedical Books; 2004.
 14. Hartzell S, Seneff S. Impaired sulfate metabolism 
and epigenetics: is there a link in autism? Entro-
py. 2012;14(10):1953–1977.
 15. Tan WH, et al. Isolated sulfite oxidase deficiency: 
a case report with a novel mutation and review of 
the literature. Pediatrics. 2005;116(3):757–766.
 16. Schwarz G. Molybdenum cofactor bio-
synthesis and deficiency. Cell Mol Life Sci. 
2005;62(23):2792–2810.
 17. Belaidi AA, Arjune S, Santamaria-Araujo JA, Sass 
JO, Schwarz G. Molybdenum cofactor deficiency: 
a new HPLC method for fast quantification of 
s-sulfocysteine in urine and serum. JIMD Rep. 
2012;5:35–43.
 18. Mechler K, Mountford WK, Hoffmann GF, 
Ries M. Ultra-orphan diseases: a quan-
titative analysis of the natural history of 
molybdenum cofactor deficiency. Genet Med. 
2015;17(12):965–970.
 19. Schwahn BC, et al. Efficacy and safety of cyclic 
pyranopterin monophosphate substitution 
in severe molybdenum cofactor deficiency 
type A: a prospective cohort study. Lancet. 
2015;386(10007):1955–1963.
 20. Lee HJ, et al. Molybdenum cofactor-deficient 
mice resemble the phenotype of human patients. 
Hum Mol Genet. 2002;11(26):3309–3317.
 21. Veldman A, et al. Successful treatment of molyb-
denum cofactor deficiency type A with cPMP. 
Pediatrics. 2010;125(5):e1249–e1254.
 22. Belaidi AA, Röper J, Arjune S, Krizowski S, Tri-
funovic A, Schwarz G. Oxygen reactivity of mam-
malian sulfite oxidase provides a concept for the 
treatment of sulfite oxidase deficiency. Biochem J. 
2015;469(2):211–221.
 23. Olney JW, Misra CH, de Gubareff T. Cysteine-S- 
sulfate: brain damaging metabolite in sulfite 
oxidase deficiency. J Neuropathol Exp Neurol. 
1975;34(2):167–177.
 24. Ye HB, Shi HB, Yin SK. Mechanisms underlying 
taurine protection against glutamate-induced neu-
rotoxicity. Can J Neurol Sci. 2013;40(5):628–634.
 25. Belaidi AA, Schwarz G. Molybdenum cofactor 
deficiency: metabolic link between taurine and 
S-sulfocysteine. Adv Exp Med Biol. 2013;776:13–19.
 26. Zhang X, Vincent AS, Halliwell B, Wong KP. A 
mechanism of sulfite neurotoxicity: direct inhi-
bition of glutamate dehydrogenase. J Biol Chem. 
2004;279(41):43035–43045.
 27. Huettner JE, Bean BP. Block of N-methyl-D- 
aspartate-activated current by the anticonvulsant 
MK-801: selective binding to open channels. Proc 
Natl Acad Sci U S A. 1988;85(4):1307–1311.
 28. Choi DW. Calcium and excitotoxic neuronal inju-
ry. Ann N Y Acad Sci. 1994;747:162–171.
 29. Stout AK, Raphael HM, Kanterewicz BI, Klann E, 
Reynolds IJ. Glutamate-induced neuron death 
requires mitochondrial calcium uptake. Nat Neu-
rosci. 1998;1(5):366–373.
 30. Vergun O, Keelan J, Khodorov BI, Duchen MR. 
Glutamate-induced mitochondrial depolarisa-
tion and perturbation of calcium homeostasis 
in cultured rat hippocampal neurones. J Physiol 
(Lond). 1999;519 Pt 2:451–466.
 31. Liu J, Liu MC, Wang KK. Physiological and 
pathological actions of calpains in glutamatergic 
neurons. Sci Signal. 2008;1(23):tr3.
 32. Tyagarajan SK, Fritschy JM. Gephyrin: a master 
regulator of neuronal function? Nat Rev Neurosci. 
2014;15(3):141–156.
 33. Kobeissy FH, et al. Degradation of βII-spectrin 
protein by calpain-2 and caspase-3 under neuro-
toxic and traumatic brain injury conditions. Mol 
Neurobiol. 2015;52(1):696–709.
 34. Ng HK, Mahaliyana RD, Poon WS. The patho-
logical spectrum of diffuse axonal injury in 
blunt head trauma: assessment with axon 
and myelin strains. Clin Neurol Neurosurg. 
1994;96(1):24–31.
 35. Park E, Liu E, Shek M, Park A, Baker AJ. Heavy 
neurofilament accumulation and alpha- 
spectrin degradation accompany cerebellar 
white matter functional deficits following 
forebrain fluid percussion injury. Exp Neurol. 
2007;204(1):49–57.
 36. Johnson JL, Cohen HJ, Rajagopalan KV. Molec-
ular basis of the biological function of molyb-
denum. Molybdenum-free sulfite oxidase from 
livers of tungsten-treated rats. J Biol Chem. 
1974;249(16):5046–5055.
 37. Johnson JL, Rajagopalan KV, Cohen HJ. Molec-
ular basis of the biological function of molyb-
denum. Effect of tungsten on xanthine oxidase 
and sulfite oxidase in the rat. J Biol Chem. 
1974;249(3):859–866.
 38. Jones CM, Smith M, Henderson MJ. Reference 
data for cerebrospinal fluid and the utility of 
amino acid measurement for the diagnosis of 
inborn errors of metabolism. Ann Clin Biochem. 
2006;43(Pt 1):63–66.
 39. Dejanovic B, et al. Palmitoylation of geph-
yrin controls receptor clustering and plas-
ticity of GABAergic synapses. PLoS Biol. 
2014;12(7):e1001908.
 40. Förstera B, et al. Irregular RNA splicing curtails 
postsynaptic gephyrin in the cornu ammonis 
of patients with epilepsy. Brain. 2010;133(Pt 
12):3778–3794.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 7 8 jci.org   Volume 127   Number 12   December 2017
 41. Dejanovic B, et al. Exonic microdeletions of 
the gephyrin gene impair GABAergic synaptic 
inhibition in patients with idiopathic generalized 
epilepsy. Neurobiol Dis. 2014;67:88–96.
 42. Lionel AC, et al. Rare exonic deletions implicate 
the synaptic organizer Gephyrin (GPHN) in risk 
for autism, schizophrenia and seizures. Hum Mol 
Genet. 2013;22(10):2055–2066.
 43. Harvey RJ, Topf M, Harvey K, Rees MI. The 
genetics of hyperekplexia: more than startle! 
Trends Genet. 2008;24(9):439–447.
 44. Belaidi AA, Schwarz G. Metal insertion into 
the molybdenum cofactor: product-substrate 
channelling demonstrates the functional ori-
gin of domain fusion in gephyrin. Biochem J. 
2013;450(1):149–157.
 45. Feng G, et al. Dual requirement for gephyrin in 
glycine receptor clustering and molybdoenzyme 
activity. Science. 1998;282(5392):1321–1324.
 46. Winkelmann A, et al. Changes in neural network 
homeostasis trigger neuropsychiatric symptoms. 
J Clin Invest. 2014;124(2):696–711.
 47. Dejanovic B, et al. Simultaneous impairment 
of neuronal and metabolic function of mutated 
gephyrin in a patient with epileptic encephalopa-
thy. EMBO Mol Med. 2015;7(12):1580–1594.
 48. Thomas SJ, Grossberg GT. Memantine: a review 
of studies into its safety and efficacy in treating 
Alzheimer’s disease and other dementias. Clin 
Interv Aging. 2009;4:367–377.
 49. Kurlemann G, Debus O, Schuierer G. Dextro-
methorphan in molybdenum cofactor deficiency. 
Eur J Pediatr. 1996;155(5):422–423.
